INTRODUCTION

Among people with diabetes, polypharmacy is common. Little is known on the medication patterns according to the glucose level in the general South Australian population. The objective of this study is to assess such patterns utilising data from the North West Adelaide Health Study (NWASH).

METHODS

All households within the north west region of Adelaide, with a telephone connected and the number listed in the Electronic White Pages were eligible for selection in the North West Adelaide Health Study. The original sample (n=4060) was randomly selected and recruited by computer assisted telephone interview in 2000-2003 (Stage 1) to participate in a clinic assessment. Within each household, the person who had their birthday last and was aged 18 years or older, was selected for interview and invited to attend the study clinic. The response rate for Stage 1 was 49.4%.

The second stage of data collection for this cohort was undertaken between 2004 and 2006. Of the original living cohort, 3564 (90.1%) participants provided some Stage 2 information, and 3206 (81.0%) attended the clinic for their second visit, with diabetes status at follow-up obtained for 78.3% (n=3180) of the original participants. Fasting plasma glucose (FPG) was measured at Stage 1 and Stage 2.

At Stage 2, participants were asked to bring their current medications to the clinic. Information from the medication container labels and a series of structured questions concerning each medication was then asked. Polypharmacy was defined as having four or more prescribed medications. Complementary alternative medicine (CAM) and prescribed medicine were analysed separately.

Data were weighted by age, sex, area of residence and probability of selection in the household to ensure that the sample was representative of the north west population.

RESULTS

The mean number of prescribed medications were 1.6, 2.8, 4.0, and 4.7 across each level of FPG (<5.6, 5.6-6.0, 6.1-7.0 and >7.0 mmol/l respectively) (p<0.001) (Table 1). However, there was no significant difference in the mean number of CAM across each FPG level. In all FPG groups, the mean was approximately 0.5.

In total, 52.5%, 44.5%, 34.1% and 17.6% of those with FPG>7.0 use metformin, statins, sulfonylureas and insulin respectively; the corresponding figures were 14.5%, 38.9%, 11.5% and 5.0% among those with FPG between 6.1 and 7.0 (Table 2).

Among those with FPG >7.0 mmol/l, 66.8% used at least one antidiabetes medication. Among participants with FPG >7.0 mmol/l, 71% had HbA1c >7.0%. Only 69.2% of those with HbA1c >7.0% took antidiabetes medication.

Aspirin use was about 30% among those with FPG above 6.1 mmol/l.

Across the four levels of FPG, the prevalence of use of ACE inhibitor was 6.0%, 15.4%, 18.3% and 19.7% respectively. Polypharmacy was common among those with FPG>6.1 mmol/l (50% used ≥4 medications).

CONCLUSIONS

Multiple medicine use is common among those with abnormal FPG levels. Competing medication priorities are of concern among patients with diabetes. The low use of lipid lowering drugs among people with normal glucose level, despite high having high total blood cholesterol levels needs attention. Under use of both antidiabetes and cardioprotective drugs among people with high blood glucose is of concern. Monitoring medication use in the population especially among diabetes is warranted.